
CRBP Stock Forecast & Price Target
CRBP Analyst Ratings
Bulls say
Corbus Pharmaceuticals Holdings Inc. benefits from its diverse and innovative pipeline, particularly the promising early-stage data for CRB-701, which demonstrates a favorable risk-benefit profile and an impressive overall response rate of approximately 44% in cervical cancer, surpassing that of its competitors. Furthermore, CRB-601 shows strong potential due to its attractive preclinical evidence and ability to inhibit TGF activation within the tumor microenvironment, suggesting significant upside against key market players. The favorable early clinical data coupled with a competitive edge in safety profiles positions Corbus for potential growth, reinforcing a positive outlook on its stock performance.
Bears say
Corbus Pharmaceuticals Holdings Inc faces a negative outlook primarily due to significant concerns regarding regulatory approval for its key drug candidates, which could lead to adverse impacts on the company's share price if timelines are delayed or unmet. Additionally, the company's focus on CRB-913 is viewed as misplaced, particularly in light of comparisons to Novo Nordisk's therapeutic developments, which could inflate market expectations. Furthermore, safety concerns, particularly regarding ocular toxicity associated with Tivdak, may hinder its acceptance and adherence among patients, ultimately affecting the company's financial performance.
This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.
CRBP Analyst Forecast & Price Prediction
Start investing in CRBP
Order type
Buy in
Order amount
Est. shares
0 shares